

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/90 // 9/22	A1	(11) International Publication Number: WO 00/46385 (43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/US00/02949 (22) International Filing Date: 3 February 2000 (03.02.00) (30) Priority Data: 60/118,472 3 February 1999 (03.02.99) US (71) Applicants (for all designated States except US): THE CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US). INSTITUT PASTEUR [FR/FR]; 25-28, rue du Docteur Roux, F-75724 Paris Cedex 15 (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): CHOULIKA, André [FR/FR]; 3, rue François Mouthon, F-75015 Paris (FR). MULLIGAN, Richard, C. [US/US]; 2 Sandy Pond Road, Lincoln, MA 01773 (US). (74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: GENE REPAIR INVOLVING *IN VIVO* EXCISION OF TARGETING DNA

(57) Abstract

Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell through SCEI-induced recombination are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENE REPAIR INVOLVING
IN VIVO EXCISION OF TARGETING DNA

RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application
5 No. 60/118,472, filed February 3, 1999, the entire teachings of which are
incorporated herein by reference.

BACKGROUND OF THE INVENTION

Homologous recombination and, more specifically D-loop mediated
recombination, provide a method for genetically modifying chromosomal DNA
10 sequences in a precise way. In addition to the possibility of introducing small
precise mutations in order to alter the activity of the chromosomal DNA sequences,
such a methodology makes it possible to correct the genetic defects in genes which
can cause disease. Unfortunately, current methods for achieving homologous
recombination are inherently inefficient, in that homologous recombination or D-
15 loop recombination-mediated gene repair can usually be achieved in only a small
proportion of cells that have taken up the relevant "targeting or correcting" DNA.
For example, in cultured mammalian cells, such recombinational events usually
occur in only one in ten thousand cells which have taken up the relevant targeting or
correcting DNA. Accordingly, the use of biochemical selections are normally
20 necessary to identify and isolate cells which have successfully recombined input
DNA.

Thus, there is a need to develop new and improved methods of homologous
recombination or D-loop recombination-mediated gene repair.

SUMMARY OF THE INVENTION

25 The present invention is related to Applicants' discovery that excision of
targeting or correcting DNA from a vector within cells which have taken up the

vector significantly increased the frequency of homologous recombination and D-loop recombination-mediated gene repair in these cells. As a result, Applicants' invention relates to methods which result in excision of targeting or correcting DNA from a vector within cells which have taken up the vector. The methods comprise

5 introducing into a cell (a) a first vector which comprises a targeting DNA, wherein the targeting DNA comprises DNA homologous to a chromosomal target site and is flanked by specific restriction endonuclease site(s), and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) and is present in the first vector or a second (separate) vector which comprises a nucleic acid encoding

10 the restriction endonuclease or is introduced as the restriction endonuclease itself. In one embodiment, two vectors are introduced into cells: a first vector which comprises a targeting DNA, wherein the targeting DNA comprises DNA homologous to a chromosomal target site and is flanked by specific restriction endonuclease sites and a second vector which comprises a nucleic acid (e.g., DNA)

15 which encodes the restriction endonuclease. Alternatively, a single vector which comprises both targeting DNA, wherein the targeting DNA comprises DNA homologous to a chromosomal target site and is flanked by specific restriction endonuclease site(s), and a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s), is introduced into the cell. In the

20 embodiments described herein, the targeting DNA is flanked by a restriction endonuclease site if such a site is present at or near either or both ends of the targeting DNA. That is, there can be one restriction endonuclease site present at or near one end of the targeting DNA or there can be two such sites, one at or near each end of the targeting DNA. The restriction endonuclease site(s) are recognized

25 (cleaved) by the restriction endonuclease used in the method. As described below, the endonuclease used in the method is one whose activity does not lead to the death of cells in which it cleaves. One example of an endonuclease useful in the method is a meganuclease enzyme. Two (or more) different restriction endonucleases can be used in the present method.

The present invention relates to a method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site or sites and comprises (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector. The two can be introduced, as described above, in the same or separate vectors or a vector comprising targeting DNA flanked by specific restriction endonuclease site(s) and the endonuclease itself (not in a vector) can be introduced. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. Typically, the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which repairs the specific sequence of interest is inserted between the two arms. In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector which comprises a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding the restriction endonuclease which cleaves the specific sites present in the vector are introduced into the cell in the same vector. As used herein, chromosomal DNA adjacent to a specific sequence of interest refers to chromosomal DNA present near or next to the specific sequence of interest.

In a particular embodiment, the specific sequence of interest is a mutation.

The present invention also relates to a method of modifying a specific sequence (or gene) in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence (or gene) to be modified and (2) DNA which results in modification of the specific sequence (or gene) upon recombination between the

targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites (one at or near each end of the targeting DNA). Typically, the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which results in modification of the specific sequence (or gene) is inserted between the two arms. In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.

The invention further relates to a method of attenuating an endogenous gene of interest in a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a target site of the endogenous gene of interest and (2) DNA which attenuates the gene of interest upon recombination between the targeting DNA and the gene of interest, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. Typically, the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which attenuates the gene of interest is located between the two arms. In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.

The present invention also relates to a method of introducing a mutation into a target site of chromosomal DNA of a cell comprising introducing into the cell (a) a

first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the target site and (2) the mutation to be introduced into the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction
5 endonuclease which cleaves the restriction endonuclease site present in the first vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. Typically, the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and the mutation is located between the two arms. In another embodiment of this method, the restriction
10 endonuclease is introduced directly into the cell. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site are introduced into the cell in the same vector.

The present invention also relates to the resulting cells and to their uses, such
15 as for production of proteins or other gene products or for treatment or prophylaxis of a condition or disorder in an individual (e.g., a human or other mammal or vertebrate) arising as a result of a genetic defect (mutation). For example, cells can be produced (e.g., ex vivo) by the methods described herein and then introduced into an individual using known methods. Alternatively, cells can be modified in the
20 individual (without being removed from the individual).

Thus, the invention further relates to a method of treating or prophylaxis of a genetic disease in an individual in need thereof. In one embodiment, this method comprises introducing into the individual cells which comprise (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction
25 endonuclease site or sites and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease
30 site(s) present in the first vector. In a second embodiment, this method comprises

introducing into the individual cells which comprise (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site(s) and comprises (1) DNA homologous to chromosomal DNA and (2) DNA which repairs the specific sequence of interest upon recombination between the

5 targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. In a third embodiment, this method comprises introducing into the individual cells which comprise a vector comprising (a) targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site(s) and comprises (1) DNA homologous to

10 chromosomal DNA and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the plasmid. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. Typically, the targeting DNA is designed

15 such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which repairs the specific sequence of interest is located between the two arms.

Alternatively, in a method of treating or prophylaxis of a genetic disease in an individual in need thereof, restriction endonucleases and vectors comprising

20 targeting DNA and/or nucleic acid encoding a restriction endonuclease can be administered directly to the individual.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of an embodiment of a homologous recombination or D-loop recombination-mediated repair method described herein.

25 Figure 2 is a table which provides the results from I-SceI induced D-loop recombination-mediated repair experiments in NIH3T3 cells.

Figure 3 is a table providing examples of meganuclease enzymes.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the development of a generally useful method for significantly increasing the frequency of homologous recombination and D-loop recombination-mediated gene repair. At least *in vitro*, over 1% of a population of transfected cells can be shown to generate the desired recombinational events using the methods described herein. It is likely that these findings represent the ability to achieve homologous recombination and/or gene repair in close to 10% of successfully transfected cells (or higher) when corrected for the efficiency of transfection (the percent cells that take up DNA).

The invention relates to the use of methods which lead to the excision of homologous targeting DNA sequences from a recombinant vector within transfected cells (cells which have taken up the vector). The methods comprise introducing into cells (a) a first vector which comprises a targeting DNA, wherein the targeting DNA flanked by specific restriction endonuclease site(s) and comprises DNA homologous to a chromosomal target site, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the first vector or a second vector which comprises a nucleic acid encoding the restriction endonuclease. Alternatively, a vector which comprises both targeting DNA and a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) is introduced into the cell. Nucleic acid encoding the restriction endonuclease is also referred to herein as an expression cassette encoding the restriction endonuclease. Targeting DNA is also referred to herein as a repair matrix and correcting DNA.

In the embodiments described herein, the targeting DNA is flanked by a restriction endonuclease site if such a site is present at or near either or both ends of the targeting DNA. That is, there can be one restriction endonuclease site present at or near one end of the targeting DNA or there can be two such sites, one at or near each end of the targeting DNA.

A restriction endonuclease used in the present invention recognizes a target DNA sequence (e.g., a restriction endonuclease site) which would not lead to death of the cells upon cleavage of the DNA sequence by the restriction endonuclease. A meganuclease enzyme, which recognizes a very large DNA sequence, is an example

of a restriction endonuclease which can be used in the present invention. An example of a meganuclease enzyme is I-SceI which recognizes an 18-bp site (DNA sequence) that does not appear to be represented in murine or human DNA. Other examples of meganuclease enzymes are provided in Figure 3. Other meganuclease
5 enzymes (natural and synthetic) are known and described in the art. In a particular embodiment, a restriction endonuclease used in the present invention has a specificity of at least 6.7×10^{-10} of cleaving (cutting) frequency.

Expression of commonly used four and six base cutting restriction enzymes within cells would usually lead to cleavage of chromosomal DNA and death of the
10 cells due to the existence of many restriction sites within the cellular DNA which are recognized by the enzymes. Accordingly, such restriction enzymes are not used in the present invention.

The excision of a linear segment of DNA within cells (presumably within the nucleus) appears to generate a form of DNA which can be more efficiently utilized
15 for recombination than either circular DNA or DNA linearized *in vitro* (prior to transfection) that are introduced into cells. This may relate to the generation of a linear segment of DNA that is either more resistant to exonucleolytic degradation than linear DNA that is transfected, or perhaps to the generation of a template more capable of forming complexes with gene products essential for recombinational
20 event.

The ability to achieve homologous recombination and gene repair at high efficiency allows for the treatment of genetic diseases by true gene repair, rather than by the addition of a functional gene to genes, as is currently the major focus of gene therapy. The method described herein should not require long term expression
25 of introduced DNA *in vivo*, a common problem with current gene therapy experiments, since only the transient expression of the appropriate restriction endonuclease should be necessary to excise the 'correcting' linear segment of DNA.

The present invention relates to a method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising introducing into the cell (a) a
30 vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site or sites and comprises (1) DNA homologous to

chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector. Preferably, the targeting
5 DNA is flanked by two restriction endonuclease sites (one at or near each end of the targeting DNA). In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector which comprises a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector. In yet another embodiment
10 of this method, both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.

In a method of repairing a specific sequence of interest in chromosomal DNA of a cell, the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting
15 DNA and chromosomal DNA and, upon recombination, repair of the specific sequence of interest occurs. Thus, in a particular embodiment, the targeting DNA is designed to include (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest, wherein the homologous DNA is sufficient for recombination between the targeting DNA and chromosomal DNA, and (2) DNA
20 which repairs the specific sequence of interest upon recombination between the targeting DNA and chromosomal DNA. Typically, the homologous DNA of the targeting DNA construct flanks each end of the DNA which repairs the specific sequence of interest. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which repairs the sequence of interest is
25 located between the two arms.

In a particular embodiment, the specific sequence of interest is a mutation. Thus, in this embodiment, the invention relates to a method of repairing a mutation in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA wherein the targeting DNA is flanked by a restriction
30 endonuclease site or sites and comprises (1) DNA homologous to chromosomal

DNA adjacent to the mutation and (2) DNA which repairs the mutation upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites (one at or near each end of the targeting DNA). In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector which comprises a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.

In a method of repairing a mutation in chromosomal DNA of a cell, the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and chromosomal DNA and, upon recombination, repair of the mutation occurs. Thus, in a particular embodiment, the targeting DNA is designed to include (1) DNA homologous to chromosomal DNA adjacent to the mutation, wherein the homologous DNA is sufficient for recombination between the targeting DNA and chromosomal DNA, and (2) DNA which repairs the mutation upon recombination between the targeting DNA and chromosomal DNA. Typically, the homologous DNA of the targeting DNA construct flanks each end of the DNA which repairs the mutation. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which repairs the mutation is located between the two arms.

As used herein, a mutation refers to a nucleotide change, such as a single or multiple nucleotide substitution, deletion or insertion, in a nucleotide sequence. Preferably, the mutation is a point mutation. Chromosomal DNA which bears a mutation has a nucleic acid sequence that is different in sequence from that of the corresponding wildtype chromosomal DNA.

As used herein, chromosomal DNA adjacent to a specific sequence of interest refers to chromosomal DNA present near or next to the specific sequence of interest.

The present invention also relates to a method of modifying a specific
5 sequence (or gene) in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence (or gene) to be modified and (2) DNA which modifies the specific
10 sequence (or gene) upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the
15 restriction endonuclease. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.

In a method of modifying a specific sequence (or gene) in chromosomal DNA of a cell, the targeting DNA is designed such that homologous recombination,
20 and more preferably, D-loop mediated recombination, occurs between the targeting DNA and chromosomal DNA and, upon recombination, modification of the sequence (or gene) occurs. Thus, in a particular embodiment, the targeting DNA is designed to include (1) DNA homologous to the specific sequence (or gene) to be modified, wherein the homologous DNA is sufficient for recombination between the
25 targeting DNA and chromosomal DNA, and (2) DNA which modifies the specific sequence (or gene) upon recombination between the targeting DNA and the chromosomal DNA. Typically, the homologous DNA of the targeting DNA construct flanks each end of the DNA which modifies the specific sequence (or gene). That is, the homologous DNA is at the left and right arms of the targeting

DNA construct and the DNA which modifies the specific sequence (or gene) is located between the two arms.

The invention further relates to a method of attenuating or inactivating an endogenous gene of interest in a cell comprising introducing into the cell (a) a vector
5 comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a target site of the endogenous gene of interest and (2) DNA which attenuates or inactivates the gene of interest upon recombination between the targeting DNA and the gene of interest, and
10 (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites, as described above. In another embodiment of this method, the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease. In yet another embodiment of this method, both the
15 targeting DNA and the nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.

In a method of attenuating or inactivating an endogenous gene of interest in a cell, the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and
20 endogenous gene of interest and, upon recombination, attenuation or inactivation of the gene of interest occurs. Thus, in a particular embodiment, the targeting DNA is designed to include (1) DNA homologous to a target site of the endogenous gene of interest, wherein the homologous DNA is sufficient for recombination between the targeting DNA and the gene of interest, and (2) DNA which attenuates or inactivates
25 the gene of interest upon recombination between the targeting DNA and the gene of interest. Typically, the homologous DNA of the targeting DNA construct flanks each end of the DNA which attenuates or inactivates the gene of interest. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which attenuates or inactivates the gene of interest is located between
30 the two arms.

The present invention also relates to a method of introducing a mutation into a target site (or gene) of chromosomal DNA of a cell comprising introducing into the cell (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to
5 the target site (or gene) and (2) the mutation to be introduced into the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. In another embodiment of this method, the restriction
10 endonuclease is introduced directly into the cell. In yet another embodiment of this method, both targeting DNA and nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site, are introduced into the cell in the same vector.

In a method of introducing a mutation into a target site (or gene) of
15 chromosomal DNA of a cell, the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and the chromosomal DNA and, upon recombination, a mutation is introduced into the target site (or gene). Thus, in a particular embodiment, the targeting DNA is designed to include (1) DNA homologous to the
20 target site (or gene), wherein the homologous DNA is sufficient for recombination between the targeting DNA and the chromosomal DNA, and (2) the mutation which is introduced into the chromosomal DNA upon recombination between the targeting DNA and the chromosomal DNA. Typically, the homologous DNA of the targeting DNA construct flanks each end of the mutation. That is, the homologous DNA is at
25 the left and right arms of the targeting DNA construct and the mutation to be introduced into the chromosomal DNA (i.e., into a target site or gene) is located between the two arms.

The invention further relates to a method of treating or prophylaxis of a genetic disease in an individual in need thereof. As used herein, a genetic disease
30 refers to a disease or disorder that arises as a result of a genetic defect (mutation) in

a gene in the individual. In a particular embodiment, the genetic disease arises as a result of a point mutation in a gene in the individual.

In one embodiment, the method of treating or prophylaxis of a genetic disease in an individual in need thereof comprises introducing into (administering to) the individual cells which comprise (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector. In a second embodiment, the method comprises introducing into the individual cells which comprise (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. In a third embodiment, the method comprises introducing into the individual cells which comprise a vector comprising (a) targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the plasmid. Preferably, the targeting DNA is flanked by two restriction endonuclease sites. Typically, the homologous DNA of the targeting DNA construct flanks each end of the DNA which repairs the specific sequence of interest. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which repairs the sequence of interest is located between the two arms.

Alternatively, in a method of treating or prophylaxis of a genetic disease in an individual in need thereof, restriction endonucleases and vectors comprising targeting DNA and/or nucleic acid encoding a restriction endonuclease can be administered directly to the individual. The mode of administration is preferably at the location of the target cells. In one embodiment, the method comprises introducing into (administering to) the individual (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector. In a second embodiment, the method comprises introducing into the individual (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector. In a third embodiment, the method comprises introducing into the individual a vector comprising (a) targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the plasmid. Preferably, the targeting DNA is flanked by two restriction endonuclease sites.

The invention also relates to the generation of animal models of disease in which restriction endonuclease sites (e.g., I-SceI target sites) are introduced at the site of the disease gene for evaluation of optimal delivery techniques.

The efficiency of gene modification/repair can be enhanced by the addition expression of other gene products. The restriction endonuclease and other gene products can be directly introduced into a cell in conjunction with the correcting DNA or via RNA expression. The approach is applicable to all organisms.

- 5 Targeting DNA can be manufactured according to methods generally known in the art. For example, targeting DNA can be manufactured by chemical synthesis or recombinant DNA/RNA technology (see, e.g., Sambrook *et al.*, Eds., *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor University Press, New York (1989); and Ausubel *et al.*, Eds., *Current Protocols In Molecular*
10 *Biology*, John Wiley & Sons, New York (1997)).

A "target site", as used herein, refers to a distinct chromosomal location at which a chromosomal DNA sequence is to be modified in a precise way in accordance with the methods described herein.

- As used herein, a "vector" includes a nucleic acid vector, e.g., a DNA vector,
15 such as a plasmid, a RNA vector, virus or other suitable replicon (e.g., viral vector).

- Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA
20 viruses such as picornavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of
25 retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J.M., *Retroviridae: The viruses and their replication*, *In Fundamental Virology*, Third Edition, B.N. Fields, *et al.*, Eds., Lippincott-Raven Publishers, Philadelphia, 1996). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse
30 mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma

virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other examples of vectors are described, for example, in McVey et al., U.S. Patent No. 5,801,030, 5 the teachings of which are incorporated herein by reference.

A vector comprising a nucleic acid encoding a restriction endonuclease contains all or part of the coding sequence for the restriction endonuclease operably linked to one or more expression control sequences whereby the coding sequence is under the control of transcription signals to permit production or synthesis of the 10 restriction endonuclease. Such expression control sequences include promoter sequences, enhancers, and transcription binding sites. Selection of the promoter will generally depend upon the desired route for expressing the restriction endonuclease. The elements can be isolated from nature, modified from native sequences or manufactured *de novo* (e.g., by chemical synthesis or recombinant DNA/RNA 15 technology, according to methods known in the art (see, e.g., Sambrook *et al.*, Eds., *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor University Press, New York (1989); and Ausubel *et al.*, Eds., *Current Protocols In Molecular Biology*, John Wiley & Sons, New York (1997)). The elements can then be isolated and fused together by methods known in the art, such as exploiting and 20 manufacturing compatible cloning or restriction sites.

Similarly, a vector comprising targeting DNA flanked by a restriction endonuclease site can be manufactured according to methods generally known in the art. For example, the vector comprising targeting DNA flanked by a restriction endonuclease site can be manufactured by chemical synthesis or recombinant 25 DNA/RNA technology (see, e.g., Sambrook *et al.*, Eds., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor University Press, New York, 1989; and Ausubel *et al.*, Eds., *Current Protocols In Molecular Biology*, John Wiley & Sons, New York, 1994-1997).

Vectors comprising targeting DNA flanked by a restriction endonuclease site 30 and/or nucleic acid encoding a restriction endonuclease can be introduced into a cell

by a variety of methods (e.g., transformation, transfection, direct uptake, projectile bombardment, using liposomes). Examples of suitable methods of transfecting or transforming cells include calcium phosphate precipitation, electroporation, microinjection, infection, lipofection and direct uptake. Such methods are described
5 in more detail, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor University Press, New York (1989); and Ausubel, *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1998), the teachings of which are incorporated herein by reference.

A vector comprising targeting DNA flanked by a restriction endonuclease
10 site and/or nucleic acid encoding a restriction endonuclease can also be introduced into a cell by targeting the vector to cell membrane phospholipids. For example, targeting of a vector of the present invention can be accomplished by linking the vector molecule to a VSV-G protein, a viral protein with affinity for all cell membrane phospholipids. Such a construct can be produced using methods well
15 known to those practiced in the art.

Restriction endonucleases can be introduced into a cell according to methods generally known in the art which are appropriate for the particular restriction endonuclease and cell type. For example, a restriction endonuclease can be introduced into a cell by direct uptake, microinjection, calcium phosphate
20 precipitation, electroporation, infection, and lipofection. Such methods are described in more detail, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor University Press, New York (1989); and Ausubel, *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1998). Other suitable methods are also described in the
25 art. The restriction endonuclease can be coupled to a facilitator of protein entry to facilitate introduction of the enzyme into a cell. Examples of facilitators of protein entry include tat, HSV VP22 and anthrax toxin. Coupling of a protein to a facilitator of protein entry can be accomplished using methods well known to those practiced in the art. Protein delivery strategies (e.g., HSV VP22, anthrax toxin) can be
30 evaluated in accordance with the methods of the invention described herein.

Once in the cell, the restriction endonuclease and the vector comprising targeting DNA flanked by a restriction endonuclease site and/or nucleic acid encoding a restriction endonuclease are imported or translocated by the cell from the cytoplasm to the site of action in the nucleus.

5 As used herein, a cell refers to a prokaryotic cell, such as a bacterial cell, or eukaryotic cell, such as an animal, plant or yeast cell. A cell which is of animal or plant origin can be a stem cell or somatic cell. Suitable animal cells can be of, for example, mammalian, avian or invertebrate origin. Examples of mammalian cells include human (such as HeLa cells), bovine, ovine, porcine, murine (such as
10 embryonic stem cells), rabbit and monkey (such as COS1 cells) cells. The cell may be an embryonic cell, bone marrow stem cell or other progenitor cell. Where the cell is a somatic cell, the cell can be, for example, an epithelial cell, fibroblast, smooth muscle cell, blood cell (including a hematopoietic cell, red blood cell, T-cell, B-cell, etc.), tumor cell, cardiac muscle cell, macrophage, dendritic cell, neuronal
15 cell (e.g., a glial cell or astrocyte), or pathogen-infected cell (e.g., those infected by bacteria, viruses, virusoids, parasites, or prions).

The cells can be obtained commercially or from a depository or obtained directly from an individual, such as by biopsy. The cells used can be obtained from an individual to whom they will be returned or from another/different individual of
20 the same or different species. For example, nonhuman cells, such as pig cells, can be modified to include a DNA construct and then introduced into a human. Such a treating procedure is sometimes referred to as *ex vivo* treatment. *Ex vivo* therapy has been described, for example, in Kasid *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:473 (1990); Rosenberg *et al.*, *N. Engl. J. Med.*, 323:570 (1990); Williams *et al.*, *Nature*,
25 310:476 (1984); Dick *et al.*, *Cell*, 42:71 (1985); Keller *et al.*, *Nature*, 318:149 (1985); and Anderson *et al.*, United States Patent No. 5,399,346. Alternatively, the cells need not be isolated from the individual where, for example, it is desirable to deliver the vector to the individual in gene therapy.

As used herein, the term "individual" includes mammals, as well as other
30 animals (e.g., birds, fish, reptiles, insects). The terms "mammal" and "mammalian",

as used herein, refer to any vertebrate animal, including monotremes, marsupials and placental, that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals). Examples of mammalian species include humans and other primates (e.g., monkeys, chimpanzees), rodents (e.g., rats, mice, guinea pigs) and ruminants (e.g., cows, pigs, horses).

Restriction endonucleases and vectors which comprise targeting DNA flanked by a restriction endonuclease site and/or nucleic acid encoding a restriction endonuclease can be introduced into an individual using routes of administration generally known in the art (e.g., parenteral, mucosal, nasal, injection, systemic, implant, intraperitoneal, oral, intradermal, transdermal (e.g., in slow release polymers), intramuscular, intravenous including infusion and/or bolus injection, subcutaneous, topical, epidural, buccal, rectal, vaginal, etc.). The restriction endonucleases and vectors can, preferably, be administered in a pharmaceutically acceptable carrier, such as saline, sterile water, Ringer's solution, and isotonic sodium chloride solution. The mode of administration is preferably at the location of the target cells.

The dosage of restriction endonuclease or vector of the present invention administered to an individual, including frequency of administration, will vary depending upon a variety of factors, including mode and route of administration; size, age, sex, health, body weight and diet of the recipient; nature and extent of symptoms of the disease or disorder being treated; kind of concurrent treatment, frequency of treatment, and the effect desired.

The present invention will now be illustrated by the following examples, which are not to be considered limiting in any way.

EXAMPLES

Example 1 Plasmid Construction

All DNA manipulations used standard techniques and procedures. Such methods are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor University Press, New York (1989); and Ausubel, *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1998). All synthetic oligonucleotides were synthesized on automated instruments using standard techniques.

The p2Wlac plasmid was constructed as follows: First, the pPytknslacZ plasmid (Henry *et al.*, *C. R. Acad. Sci. III*, 322(12):1061-1070 (1999)) was digested with the *SpeI* and *HindIII* restriction enzymes, resulting in excision from the plasmid of a 578 bp fragment containing the ATG start codon and 178 bp at the 5' end of the coding region of the *nslacZ* gene. Second, the oligonucleotide 5'-CTAGATGCATAGGGATAACAGGGTAAT-3' (SEQ ID NO:1), paired with 5'-AGCTATTACCCTGTTATCCCTATGCAT-3' (SEQ ID NO:2), was inserted into the *SpeI-Hind III* restriction sites of the pPytknslacZ plasmid (Henry *et al.*, *C. R. Acad. Sci. III*, 322(12):1061-1070 (1999)) to produce the pWnslacZ plasmid. Insertion of the oligonucleotide at the *SpeI-Hind III* restriction sites resulted in destruction of the *SpeI* and *HindIII* restriction sites and insertion of a *NsiI* restriction site and an *I-SceI* restriction site. The pWnslacZ plasmid was then digested with the *NheI* and *BglII* restriction enzymes, resulting in excision from the plasmid of a 0.6 kb fragment containing the stop codon and SV40 polyadenylation signal at the 3' end of the *nslacZ* gene. The oligonucleotide 5'-GATCATGCATAGGGATAACAGGGTAAT-3' (SEQ ID NO:3), paired with 5'-CTAGATTACCCTGTTATCCCTATGCAT-3' (SEQ ID NO:4), was inserted into the *NheI-BglII* restriction sites of the pWnslacZ plasmid. Insertion of the oligonucleotide at the *NheI-BglII* restriction sites resulted in destruction of the *NheI* and the *BglII* restriction sites and insertion of an *I-SceI* restriction site and a *NsiI* restriction site. The result of these insertions is the p2Wlac plasmid in which the

nslacZ gene with the ATG start codon, 178 bp at the 5' end, stop codon and SV40 polyadenylation signal deleted, is inserted between two I-SceI sites. As a result of the deletion of the start codon and 178 bp at the 5' end of the coding region, *nslacZ* gene expression is inactivated.

5 The pWlac plasmid was constructed as follows: First, the pPytknslacZ plasmid was digested with the *SpeI* and *HindIII* restriction enzymes, resulting in excision from the plasmid of a 578 bp fragment containing the ATG start codon and 178 bp at the 5' end of the coding region of the *nslacZ* gene. Second, the oligonucleotide 5'-CTAGATGCATAGGGATAACAGGGTAAT-3' (SEQ ID NO:1),
10 paired with 5'-AGCTATTACCCTGTTATCCCTATGCAT-3' (SEQ ID NO:2), was inserted into the *SpeI*-*HindIII* restriction sites of the pPytknslacZ plasmid to produce the pWnslacZ plasmid. Insertion at this restriction site resulted in destruction of the *SpeI* and *HindIII* restriction sites and the insertion of an *NsiI* restriction site and an I-SceI restriction site. The pWnslacZ plasmid was digested
15 with the *NheI* and *BglII* restriction enzymes, resulting in excision from the plasmid of the 0.6 kb fragment containing the stop codon and SV40 polyadenylation signal at the 3' end of the *nslacZ* gene. The 5' extensions of the *NheI*-*BglII* restriction sites of the pWnslacZ plasmid were converted to blunt ends by a filling-in reaction using T4 DNA polymerase. The blunted ends were then ligated together. The result is the
20 pWlac plasmid in which the *nslacZ* gene with the ATG start codon, 178 bp at the 5' end, stop codon and SV40 polyadenylation signal deleted, is bounded at the 5' end by one I-SceI site; the 3' end of the *nslacZ* gene is not bounded by a I-SceI site. As a result of the deletion of the start codon and 178 bp at the 5' end of the coding region, *nslacZ* gene expression is inactivated.

25 The p-lac plasmid was constructed as follows: First, the pPytknslacZ plasmid was digested with the *SpeI* and *HindIII* restriction enzymes, resulting in excision from the plasmid of a 578 bp fragment containing the ATG start codon and 178 bp at the 5' end of the coding region of the *nslacZ* gene. The 5' extensions of the *SpeI*-*HindIII* restriction sites of the pPytknslacZ plasmid were converted to
30 blunt ends by a filling-in reaction using T4 DNA polymerase. The blunted ends

were then ligated together to produce the p-lacZ plasmid. The p-lacZ plasmid was digested with the *NheI* and *BglIII* restriction enzymes, resulting in excision from the plasmid of the 0.6 kb fragment containing the stop codon and SV40 polyadenylation signal at the 3' end of the *nls lacZ* gene. The 5' extensions of the *NheI-BglIII* restriction sites of the pWnslacZ plasmid were converted to blunt ends by a filling-in reaction using T4 DNA polymerase. The blunted ends were then ligated together. The result is the p-lac plasmid in which the *nls lacZ* gene with the ATG start codon, 178 bp at the 5' end, stop codon and SV40 polyadenylation signal deleted, is not bounded at the 5' or 3' end by a *I-SceI* site. As a result of the deletion of the start codon and 178 bp at the 5' end of the coding region, *nls lacZ* gene expression is inactivated.

The 2.8 kb linear fragment of the *nls lacZ* gene used in the experiments described herein was obtained as follows: The pPytknslacZ plasmid was digested with *NheI* and *HindIII* and a 2.8 kb fragment was purified by agarose gel electrophoresis. This 2.8 kb fragment, referred to herein as the lac fragment, contains a fragment of the *nls lacZ* gene with the ATG start codon, 178 bp at the 5' end, stop codon and SV40 polyadenylation signal deleted.

The pCMV *I-SceI*(+) and pCMV *I-SceI*(-) plasmids were described in Chouluka *et al.*, *C. R. Acad. Sci. III*, 317(11):1013-1019 (1994).

The target plasmid pPytknslacZDBcl was produced by digesting the pPytknslacZ plasmid with the *BclI* restriction enzyme after demethylation of the plasmid. The 5' protruding ends were filled-in by the Klenow fragment of *E. coli* DNA polymerase I and religated. The result is insertion of a 4 base pair direct repeat in the sequence of the *nls lacZ* gene resulting in a frame shift of the open reading frame, thereby inactivating expression of the gene. Thus, the plasmid does not express the β -galactosidase protein.

The target plasmid pPytknslacZ Δ Bcl was produced by digesting the pPytknslacZ plasmid with the *BclI* restriction enzyme after demethylation of the plasmid. The 4 base pair 5' protruding ends were degraded by T4 DNA polymerase and the resulting blunted ends religated. The result is deletion of 4 base pairs within

the sequence of the *nls lacZ* gene resulting in a frame shift of the open reading frame, thereby inactivating expression of the gene. Thus, the plasmid does not the β -galactosidase protein.

The pUSVneo plasmid was described in Chouluka *et al.*, *J. Virol.*,
5 70(3):1792-1798, (1996).

Example 2 Cell Line Production and D-loop Recombination: Correction Of A 4 Base Pair Insertion

5 μ g of the pPytknslacZDBcl plasmid and 5 μ g of the pUSVneo plasmid were co-transfected into 5×10^4 NIH 3T3 cells (American Type Culture Collection) in a 35 mm petri dish (Falcon) using the CaPO_4 precipitation method. 48 hours after
10 transfection, the tissue culture medium was supplemented with 600 μ g/ml of Geneticin (Gibco BRL). Antibiotic selection was maintained during selection of Geneticin resistant clones and during subcloning. Forty-eight (48) Geneticin resistant clones were isolated and grown independently in Dulbeccos modified
15 Eagles Medium (DMEM), 10% calf serum, for 15 days before evaluating for the presence of the *nls lacZ* gene.

To evaluate for presence of the *nls lacZ* gene, DNA was extracted from cells in all 48 cultures of Geneticin resistant clones. Fragments of the *nls lacZ* gene were amplified by polymerase chain reaction (PCR) as described in *BioFeedback in*
20 *BioTechniques*, Hanley & J. P. Merlie, Vol. 10, No. 1, p. 56T (1991). Forty-six (46) of 48 clones were positive for the presence of the *nls lacZ* gene.

Twenty-four (24) of the 46 clones positive for the presence of the *nls lacZ* gene were evaluated for expression of the mutated *nls lacZ* gene. To evaluate for expression of the mutated *nls lacZ* gene, RNA was extracted from cells in the
25 corresponding 24 cultures of Geneticin resistant clones. RNA encoding the mutated *nls lacZ* gene was amplified by reverse transcriptase polymerase chain reaction (RT-PCR). The oligonucleotide primer 5'-TACACGCGTCGTGATTAGCGCCG-3' (SEQ ID NO:5) was used for lacZ reverse transcription. PCR was performed as

described in *BioFeedback in BioTechniques*, Hanley & J. P. Merlie, Vol. 10, No. 1, p. 56T (1991). Eleven (11) of 24 clones showed a positive reaction.

Southern blot analysis of the genomic DNA of these 11 clones was performed and 3 clones were shown to have less than 3 intact copies of the
5 pPytknslacZDBcl construct.

Histochemical analysis of these 3 clones was performed by X-Gal staining as described in Bonnerot *et al.*, *Methods in Enzymology, Guide To Techniques In Mouse Development*, Academic Press, pp. 451-469 (1993). Two (2) of 3 clones showed expression of β -galactosidase in less than 1×10^6 cells. β -galactosidase in
10 these cells is probably the result of intragenic recombination of the 4 bp direct repeat inserted into the *Bcl*I restriction site. Northern blot analysis of the mRNA expressed by the integrated pPytknslacZDBcl construct showed very little expression for one of the clones (the one with no background expression) and strong signals for two other clones (the ones expressing β -galactosidase in less than 1×10^6 cells). These
15 two cell lines, NIH 3T3 DBcl1 and NIH 3T3 DBcl2, were selected to be the targets to the D-loop recombination.

Ex vivo Recombination In NIH 3T3 DBcl1 And NIH 3T3 DBcl2 Cell Lines

Three sets of experiments were performed, in triplicate, using the NIH 3T3 DBcl1 and NIH 3T3 DBcl2 cell lines. Each set of experiment, in triplicate,
20 comprises 8 different cotransfections of DNA mixes as shown in Table 1. Transfections were performed in either 5×10^4 NIH 3T3 DBcl1 cells or 5×10^4 NIH 3T3 DBcl2 cells in a 60 mm petri dish (Falcon) using the CaPO_4 precipitation method.

TABLE 1

Mix Number	Expression Plasmid	Quantity	Repair Matrix	Quantity
1	pCMV I-SceI(+)	9 μ g	p2Wlac	1 μ g
2	pCMV I-SceI(+)	9 μ g	pWlac	1 μ g
3	pCMV I-SceI(+)	9 μ g	p-lac	1 μ g
4	pCMV I-SceI(+)	9 μ g	lac	1 μ g
5	pCMV I-SceI(-)	9 μ g	p2Wlac	1 μ g
6	pCMV I-SceI(-)	9 μ g	pWlac	1 μ g
7	pCMV I-SceI(-)	9 μ g	p-lac	1 μ g
8	pCMV I-SceI(-)	9 μ g	lac	1 μ g

96 hours after transfection, cells were stained for β -galactosidase expression in X-Gal and blue colony forming units (bcfu) were counted. The number of bcfu is the result of the D-loop correction in each of the experiment. Results are shown in Figure 3.

Transfection of NIH 3T3 DBcl2 cells with mix number 1 (pCMV I-SceI(+), 9 μ g; p2Wlac, 1 μ g) gave a 3 to 5% of β -galactosidase positive clones (out of three experiments) as the higher rate of D-loop correction of the pPytknslacZDBcl mutated plasmid. Thus, after transfection of 1×10^5 cells with mix number 1, 96 individual cells were cloned by limit dilution according to standard methods. Cells were grown in DMEM, 10% calf serum, and analyzed for β -galactosidase expression. Five (5) of 71 clones showed more than 1×10^6 cells expressing β -galactosidase (ranging between 5 to 80% of the cells). Southern blot analysis of these 5 clones showed that 100% of the cells had their *nls lacZ* gene with a *BclI* site recovered. The lack of correspondence between the expression of the intact *nls lacZ* open reading frame and the total repair of the genome is probably the result of transgene variegation.

Example 3 Cell Line Production and D-loop Recombination: Correction Of A 4
Base Pair Deletion

5 5 µg of the pPytknslacZΔBcl plasmid and 5 µg of the pUSVneo plasmid
were cotransfected in 5×10^4 NIH 3T3 cells (American Type Culture Collection) in a
35 mm petri dish (Falcon) using the CaPO_4 precipitation method. 48 hours after
transfection, the tissue culture medium was supplemented with 600 µg/ml of
Geneticin (Gibco BRL). Antibiotic selection was maintained during selection of
Geneticin resistant clones and during subcloning. Forty-eight (48) Geneticin
resistant clones were isolated and grown independently in Dulbeccos modified
10 Eagles Medium (DMEM), 10% calf serum, for 15 days before evaluating for the
presence of the *nslacZ* gene.

To evaluate for presence of the *nslacZ* gene, DNA was extracted from cells
in all 48 cultures of Geneticin resistant clones. Fragments of the *nslacZ* gene were
amplified by PCR as described in *BioFeedback in BioTechniques*, Hanley & J. P.
15 Merlie, Vol. 10, No. 1, p. 56T (1991). Forty-eight (48) of 48 clones were positive
for the presence of the *nslacZ* gene.

Twenty-four (24) of the 48 clones positive for the presence of the *nslacZ*
gene were evaluated for expression of the mutated *nslacZ* gene. To evaluate for
expression of the mutated *nslacZ* gene, RNA was extracted from cells in the
20 corresponding 24 cultures of Geneticin resistant clones. RNA encoding the mutated
nslacZ gene was amplified by RT-PCR. The oligonucleotide primer
5'-TACACGCGTCGTGATTAGCGCCG-3' (SEQ ID NO:5) was used for lacZ
reverse transcription. PCR was performed as described in *BioFeedback in*
BioTechniques, Hanley & J. P. Merlie, Vol. 10, No. 1, p. 56T (1991). Nine (9) of 24
25 clones showed a positive reaction.

Southern blot analysis of the genomic DNA of these 9 clones was performed
and 1 clone was shown to have less than 3 intact copies of the pPytknslacZΔBcl
construct.

Histochemical analysis of these 4 clones was performed by X-Gal staining as
30 described in Bonnerot *et al.*, *Methods in Enzymology, Guide To Techniques In*
Mouse Development, Academic Press, pp. 451-469 (1993). No clones showed

expression of β -galactosidase. No intragenic recombination can occur in these cell lines. Northern blot analysis of the mRNA expressed by the integrated pPytknslacZ Δ Bcl construct showed very little expression for two of the clones and strong signals for the other two clones. These two cell lines, NIH 3T3 Δ Bcl1 and
 5 NIH 3T3 Δ Bcl2, were selected to be the targets to the D-loop recombination.

Ex vivo Recombination In NIH 3T3 Δ Bcl1 And NIH 3T3 Δ Bcl2 Cell Lines

Three sets of experiments were performed, in triplicate, using the NIH 3T3 Δ Bcl1 and NIH 3T3 Δ Bcl2 cell lines. Each set of experiment, in triplicate, comprises 8 different cotransfections of DNA mixes as shown in Table 2.

10 Transfections were performed in either 5×10^4 NIH 3T3 Δ Bcl1 cells or 5×10^4 NIH 3T3 Δ Bcl2 cells in a 60 mm petri dish (Falcon) by the CaPO_4 precipitation method.

TABLE 2

Mix Number	Expression Plasmid	Quantity	Repair Matrix	Quantity
15 1	pCMV I-SceI(+)	9 μ g	p2Wlac	1 μ g
2	pCMV I-SceI(+)	9 μ g	pWlac	1 μ g
3	pCMV I-SceI(+)	9 μ g	p-lac	1 μ g
4	pCMV I-SceI(+)	9 μ g	lac	1 μ g
5	pCMV I-SceI(-)	9 μ g	p2Wlac	1 μ g
20 6	pCMV I-SceI(-)	9 μ g	pWlac	1 μ g
7	pCMV I-SceI(-)	9 μ g	p-lac	1 μ g
8	pCMV I-SceI(-)	9 μ g	lac	1 μ g

96 hours after transfection, cells were stained for β -galactosidase expression in X-Gal and blue colony forming units (bcfu) were counted. The number of bcfu is
 25 the result of the D-loop correction in each of the experiment. Results are shown in Figure 3.

Transfection of NIH 3T3 Δ Bcl2 with mix number 1 (pCMV I-SceI(+), 9 μ g; p2Wlac, 1 μ g) gave a 1 to 3% of β -galactosidase positive clones (out of the three experiments) as the higher rate of D-loop correction of the pPytknslacZ Δ Bcl mutated plasmid. Thus, after transfection of 1×10^5 cells with mix number 1, 96 individual cells were cloned by limit dilution. Cells were grown in DMEM, 10% calf serum, and analyzed for β -galactosidase expression. Two (2) of 66 clones showed cells expressing β -galactosidase (ranging between 30 to 80% of the cells). Southern blot analysis of these 2 clones showed that 100% of the cells had their *nslacZ* gene with a *Bcl* I site recovered. The lack of correspondence between the expression of the intact *nslacZ* open reading frame and the total repair of the genome is probably the result of transgene variegation.

Example 4 I-SceI induced D-loop Recombination

The pPytknslacZD-Bcl construct is integrated into the genomic DNA of NIH 3T3 cells as described in Example 2. In these cells, the *nslacZ*DBcl gene is transcribed but β -galactosidase expression is not detected (β -gal⁻ cells). β -gal⁻ cells are cotransfected with the p2Wlac plasmid containing two I-SceI sites and an expression vector coding for I-SceI endonuclease. The p2Wlac plasmid is linearized *in vivo* by the I-SceI endonuclease and correct the DBcl mutation by D-loop recombination. As a result, these cells contain a pPytknslacZ plasmid that expresses β -galactosidase (β -gal⁺ cells). A schematic diagram of this experiment is depicted in Figure 1.

The teachings of all the articles, patents and patent applications cited herein are incorporated by reference in their entirety.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

CLAIMS

What is claimed is:

1. A method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising the steps of:
 - 5 a) introducing into said cell a first vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between
10 said targeting DNA and the chromosomal DNA; and
 - b) introducing into said cell a second vector comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
2. The method of Claim 1 wherein the first vector is a viral vector.
- 15 3. The method of Claim 1 wherein the second vector is a viral vector.
4. The method of Claim 1 wherein the first vector is a plasmid.
5. The method of Claims 1 wherein said targeting DNA is flanked by two restriction endonuclease sites, one site present at or near the 5' end of said targeting DNA and one site present at or near the 3' end of said targeting
20 DNA.
6. The method of Claims 1 wherein the specific sequence of interest is a mutation.

7. A method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising the steps of:
- 5 a) introducing into said cell a vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between said targeting DNA and the chromosomal DNA; and
- 10 b) introducing into the cell a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
8. The method of Claim 7 wherein the vector is a viral vector.
9. The method of Claim 7 wherein said targeting DNA is flanked by two restriction endonuclease sites.
10. The method of Claims 7 wherein the specific sequence of interest is a mutation.
- 15 11. A method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising introducing into the cell a vector comprising (a) targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between said targeting DNA and the chromosomal DNA; and (b) a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site.
- 20 12. The method of Claim 11 wherein the vector is a viral vector.

13. The method of Claims 11 wherein said targeting DNA is flanked by two restriction endonuclease sites.
14. The method of Claims 11 wherein the specific sequence of interest is a mutation.
- 5 15. A method of modifying a specific sequence in chromosomal DNA of a cell comprising the steps of:
- 10 a) introducing into the cell a first vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence to be modified and (2) DNA which modifies the specific sequence upon recombination between said targeting DNA and the chromosomal DNA; and
- 15 b) introducing into the cell a second vector comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
16. The method of Claim 15 wherein the first vector is a viral vector.
17. The method of Claim 15 wherein the second vector is a viral vector.
18. The method of Claim 17 wherein the first vector is a plasmid.
19. The method of Claims 15 wherein said targeting DNA is flanked by two restriction endonuclease sites.
- 20 20. A method of modifying a specific sequence in chromosomal DNA of a cell comprising the steps of:

- 5 a) introducing into the cell a vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence to be modified and (2) DNA modifies the specific sequence upon recombination between said targeting DNA and the chromosomal DNA; and
- 10 b) introducing into the cell a restriction endonuclease which cleaves the restriction endonuclease site present in the vector, under conditions appropriate for the restriction endonuclease to cleave the restriction endonuclease site in the vector of step a).
21. The method of Claim 20 wherein the vector is a viral vector.
22. The method of Claim 20 wherein said targeting DNA is flanked by two restriction endonuclease sites.
- 15 23. A method of modifying a specific sequence in chromosomal DNA of a cell comprising introducing into the cell a vector comprising (a) targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence to be modified and (2) DNA which results in modification of the specific sequence upon recombination between said targeting DNA and the chromosomal DNA; and
- 20 (b) a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site.
24. The method of Claim 23 wherein the vector is a viral vector.
25. The method of Claims 23, wherein said targeting DNA is flanked by two restriction endonuclease sites.

26. A method of treating or prophylaxis of a genetic disease in an individual in need thereof comprising the steps of:
- 5 a) introducing into the individual cells which comprise a first vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between said targeting DNA and the chromosomal DNA; and
- 10 b) introducing into the individual a second vector comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
27. The method of Claim 26 wherein the first vector is a viral vector.
28. The method of Claim 27 wherein the second vector is a viral vector.
- 15 29. The method of Claim 27 wherein the first vector is a plasmid.
30. The method of Claims 24 wherein said targeting DNA is flanked by two restriction endonuclease sites.
31. A method for treating or prophylaxis of a genetic disease in an individual in need thereof comprising the steps of:
- 20 a) introducing into the individual cells which comprise a vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon

recombination between said targeting DNA and the chromosomal DNA; and

- b) introducing into the cell a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.

5 32. The method of Claim 31 wherein the vector is a viral vector.

33. The method of Claim 31 wherein said targeting DNA is flanked by two restriction endonuclease sites.

34. A method of attenuating an endogenous gene of interest in a cell comprising the steps of:

- 10 a) introducing into the cell a first vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a targeting site of the endogenous gene of interest and (2) DNA which attenuates the gene of interest upon recombination between said targeting DNA and the
- 15 b) introducing into the cell a second vector comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.

35. The method of Claim 34 wherein the first vector is a viral vector.

20 36. The method of Claim 34 wherein the second vector is a viral vector..

37. The method of Claim 34 wherein the first vector is a plasmid.

38. The method of Claims 34 wherein said targeting DNA is flanked by two restriction endonuclease sites.

39. A method of attenuating an endogenous gene of interest in a cell comprising the steps of:
- 5 a) introducing into the cell a vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a targeting site of the endogenous gene of interest and (2) DNA which attenuates the gene of interest upon recombination between said targeting DNA and the gene of interest; and
- 10 b) introducing into the cell a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
40. The method of Claim 39 wherein the vector is a viral vector.
41. The method of Claim 39 wherein said targeting DNA is flanked by two restriction endonuclease sites.
42. A method of attenuating an endogenous gene of interest in a cell comprising
- 15 introducing into the cell a vector comprising (a) targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a targeting site of the endogenous gene of interest and (2) DNA which attenuates the gene of interest upon recombination between said targeting DNA and the gene of interest; and (b) a nucleic acid
- 20 encoding a restriction endonuclease which cleaves the restriction endonuclease site.
43. The method of Claim 42 wherein the vector is a viral vector.
44. The method of Claims 42 wherein said targeting DNA is flanked by two restriction endonuclease sites.

45. A method of introducing a mutation into a targeting site of chromosomal DNA of a cell comprising the steps of:
- a) introducing into the cell a first vector comprising targeting DNA, wherein said is flanked by a restriction endonuclease site and comprises (1) DNA homologous to said target site and (2) the mutation to be introduced into the chromosomal DNA; and
 - b) introducing into the cell a second vector comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
46. The method of Claim 45 wherein the first vector is a viral vector.
47. The method of Claim 45 wherein the second vector is a viral vector.
48. The method of Claim 47 wherein the first vector is a plasmid.
49. The method of Claims 45 wherein said targeting DNA is flanked by two restriction endonuclease sites.
50. A method of introducing a mutation into a target site of chromosomal DNA of a cell comprising the steps of:
- a) introducing into the cell a vector comprising targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the target site and (2) the mutation to be introduced into the chromosomal DNA; and
 - b) introducing into the cell a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
51. The method of Claim 50 wherein the vector is a viral vector.

52. The method of Claim 50 wherein said targeting DNA is flanked by two restriction endonuclease sites.
53. A method of introducing a mutation into a target site of chromosomal DNA of a cell comprising introducing into the cell a vector comprising (a) targeting DNA, wherein said targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the target site and (2) the mutation to be introduced into the chromosomal DNA; and (b) a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site.
54. The method of Claim 53 wherein the vector is a viral vector.
55. The method of Claims 53 wherein said targeting DNA is flanked by two restriction endonuclease sites.




FIG. 1

2/3





% age of β -gal expressing cells		No I-SceI site 	2 I-SceI sites 	1 I-SceI sites 	linear fragment 
4 bp deletion repair	I-SceI +	0	0.8-1.2	0.09	0.001
	I-SceI -	0	0	0	0.001
4 bp duplication repair	I-SceI +	0	0-1.6	0.2-0.3	0.007
	I-SceI -	0	0	0	0.008

FIG. 2

3/3

Enzyme	Organism (strain)	Size	Site	Cleavage	Shape of Cleavage	GenBank Accession No.	Commercially Available
ENZYMES ENCODED BY INDEPENDENT GENES							
Endo.Sce	Saccharomyces cerevisiae (IAM 4274)	476	25	very frequent	4 /3'OH	M63839	
HO	Saccharomyces cerevisiae	586	18	very rare	4 /3'OH	M14678	
ENZYMES ENCODED BY INTRONS							
I-Ceu I	Chlamydomonas eugametos	218	20	very rare	4 /3'OH	S15138	Yes
I-Chu I	Chlamydomonas humicola	218	20	very rare	4 /3'OH	L06107	
I-Cre I	Chlamydomonas reinhardtii	163	24	very rare	4 /3'OH	X01977	
I-Csm I	Chlamydomonas smithii	237				X55305	
I-Dir I	Didymium iridis (Pan 2)	244				X71792	
I-Dmo I	Desulfurococcus mobilis	194		rare	4 /3'OH	P21505	
I-Hmu I	Bacteriophage SPO1/B. subtilis	174				M37686	
I-Hmu II	Bacteriophage SP82/B. subtilis	187					
I-Ppo I	Physarum polycephalum (Carolina)	185	15	rare	4 /3'OH	M38131	Yes
I-Sce I	Saccharomyces cerevisiae (IL8-8C/R53)	235	18	very rare	4 /3'OH	P03882	Yes
I-Sce II	Saccharomyces cerevisiae (D273-10B)	316	15	frequent	4 /3'OH	P03878	
I-Sce III	Saccharomyces cerevisiae (777-3A)	335	18	very rare	4 /3'OH	P03877	
I-Sce IV	Saccharomyces cerevisiae (777-3A)	307		rare	4 /3'OH		
I-Tev I	Bacteriophage T4/E. coli	245	39	?	2 /3'OH	M12742	
I-Tev II	Bacteriophage T4/E. coli	258	25	?	2 /3'OH		
I-Tev III	Bacteriophage RB3/E. coli	269			2 /5'P	X59078	
INTERCALATING PROTEINS							
PI-Mle I	Mycobacterium leprae	365				X73822	
PI-Mtu I	Mycobacterium tuberculosis	439				X58485	
PI-Psp I	Pyrococcus species (GB-D)	537				U00707	
PI-Tli I	Thermococcus litoralis	390	20	rare	4 /3'OH	M74198	Yes
PI-Tli II	Thermococcus litoralis	541	12	very rare	4 /3'OH	M74198	Yes
PI-Sce V	Saccharomyces cerevisiae (YFG 499)	454	12	very rare	4 /3'OH	M21609	Yes

FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/02949

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/90 //C12N9/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 14408 A (PASTEUR INSTITUT ; UNIV PARIS CURIE (FR)) 17 May 1996 (1996-05-17) figure 30	1-55
A	CHOU LIKA A ET AL: "THE YEAST I-SCE I MEGANUCLEASE INDUCES SITE-DIRECTED CHROMOSOMAL RECOMBINATION IN MAMMALIAN CELLS" COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES. SERIE III: SCIENCES DE LA VIE, NL, ELSEVIER, AMSTERDAM, vol. 317, no. 11, 1 November 1994 (1994-11-01), pages 1013-1019, XP000571580 ISSN: 0764-4469 the whole document	1-55

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

31 May 2000

Date of mailing of the international search report

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 00/ 02949

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims 26-33 are explicitly directed to a method of treatment of the human/animal body. Moreover, claims 1-25, 34-55 include methods in vivo and can therefore be directed to a method of treatment as well. The search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/02949

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9614408 A	17-05-1996	US 5792632 A	11-08-1998
		CA 2203569 A	17-05-1996
		EP 0791058 A	27-08-1997
		JP 10508478 T	25-08-1998
		US 5948678 A	07-09-1999
		US 5866361 A	02-02-1999